ReviewExpert opinion on emerging drugs2009
Emerging drugs for the treatment of ulcerative colitis.
Review in Expert opinion on emerging drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.Digestive diseases and sciences · 2016Trial
- Harnessing nature's pharmacy: investigating natural compounds as novel therapeutics for ulcerative colitis.Frontiers in pharmacology · 2024Review
- Capsular Polysaccharide FromFrontiers in pharmacology · 2020Article
- An entirely automated method to score DSS-induced colitis in mice by digital image analysis of pathology slides.Disease models & mechanisms · 2013Article
- Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling.Molecules (Basel, Switzerland) · 2012Review
- Modulating immunity as a therapy for bacterial infections.Nature reviews. Microbiology · 2012Review
- Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Targeting Toll-like receptors: emerging therapeutics?Nature reviews. Drug discovery · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) is a chronic, relapsing inflammatory disorder of the colon for which the etiology is currently unknown. At present, strategies to treat UC are primarily targeted to control inflammation during active phases of disease as well as maintain remission during quiescence. As such, several unmet needs in the treatment of UC still remain. In recent years, basic research has led to the recognition of several key factors in the pathogenesis of UC, translating into the development of several novel therapeutic agents.
objectiveThe aim of this study is to review emerging therapies that may advance the treatment and improve the overall care of UC patients.
methodsAn extensive literature search on published manuscripts and meeting proceedings has been performed to provide a comprehensive review of future drug therapies to treat UC. RESULTS/
conclusionThe translational application of new discoveries in the basic understanding of UC pathogenesis is continuing and critical for the development of novel treatment strategies. Design of novel biologic therapies to treat UC has the challenge of addressing potential safety issues, while more traditional drugs should be further developed to facilitate patient compliance to treat this chronic, debilitating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.